Sign In
Buy SLP
$16.17
-0.600 (-3.58%)
At Close: Jun 03, 2026
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
11:55pm, Wednesday, 23'rd Oct 2024
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
Simulations Plus (SLP) Surpasses Q4 Earnings Estimates
07:05pm, Wednesday, 23'rd Oct 2024
Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago.
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
04:06pm, Wednesday, 09'th Oct 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 23, 2024, at 5pm ET to discuss 4th quarter & fiscal year 2024 financial results.
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
08:30am, Tuesday, 08'th Oct 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with USC, is awarded a new research grant from the NIH to develop new AI-driven Drug Design methods.
Simulations Plus (SLP) Restructures Business Unit Post-Acquisitions
12:00pm, Monday, 26'th Aug 2024
Simulations Plus, Inc. SLP has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
08:00am, Friday, 23'rd Aug 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced strategic changes in leadership and the structure of its business units to optimize operations and support future growth.
Simulations Plus (SLP) Ties Up With ICCS for Chemical Safety
11:11am, Friday, 12'th Jul 2024
Simulations Plus, Inc. SLP has entered into a partnership with the International Collaboration on Cosmetics Safety (“ICCS”) to develop a physiologically-based kinetic (PBK) read-across strategy fo
Simulations Plus Stock Drops 15% Despite EPS Beat
09:12am, Friday, 05'th Jul 2024
Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. The firm has vastly underperformed the market and its sector over the last 12 months, with
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates
11:20am, Wednesday, 03'rd Jul 2024
Simulations Plus' (SLP) fiscal third-quarter revenues are driven by strength in Software and Services units.
Simulations Plus Posts Q3 Results, Joins First Foundation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:53am, Wednesday, 03'rd Jul 2024
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 0.2% on Wednesday.
Simulations Plus, Inc. (SLP) Q3 2024 Earnings Call Transcript
07:28pm, Tuesday, 02'nd Jul 2024
Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executiv
Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for
11:00am, Tuesday, 25'th Jun 2024
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
08:30am, Thursday, 20'th Jun 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Morgan Stanley's 3rd Annual Life Sciences AI Summit on June 26, 2024, in New York City.
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
08:30am, Tuesday, 18'th Jun 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will report 3rd quarter FY24 earnings and host a conference call to discuss the financial results on July 2, 2024, at 5pm EDT.
Simulations Plus (SLP) Upgraded to Buy: Here's Why
01:06pm, Friday, 14'th Jun 2024
Simulations Plus (SLP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
